Bank of New York Mellon’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-12,500
Closed -$489K 4334
2016
Q4
$489K Buy
+12,500
New +$509K ﹤0.01% 3604

Other funds holding XPH

Bank of New York Mellon's XPH Position: Q1 2017 in Review

Bank of New York Mellon sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2017, closing a stake of 12,500 shares — an estimated $489K sold.

Bank of New York Mellon first reported a position in XPH in Q4 2016 and held it in 1 quarter. The position peaked at $489K in Q4 2016. 79 funds tracked by Wall St. Rank hold XPH as of Q1 2017.

  • Bank of New York Mellon reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2017 after selling out during the quarter.
  • Bank of New York Mellon sold 12,500 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2017, an estimated $489K.
  • Bank of New York Mellon first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2016 and held it in 1 quarter.
  • Bank of New York Mellon's State Street SPDR S&P Pharmaceuticals ETF position peaked at $489K in Q4 2016.
  • 79 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2017.

Based on Bank of New York Mellon's 13F filing for Q1 2017, filed 3 May 2017.